Literature DB >> 19199548

Hepatitis C virus infection of T cells inhibits proliferation and enhances fas-mediated apoptosis by down-regulating the expression of CD44 splicing variant 6.

Yasuteru Kondo1, Keigo Machida, Helene Minyi Liu, Yoshiyuki Ueno, Koju Kobayashi, Takaji Wakita, Tooru Shimosegawa, Michael M C Lai.   

Abstract

BACKGROUND: A lymphotropic hepatitis C virus strain (HCV, SB strain, hereafter "SB-HCV") has been shown to infect established T cell lines (Molt-4 and Jurkat) and primary human naive CD4(+) T cells. During T cell development and activation, transient expression of CD44 splicing variant 6 (CD44v6) plays a significant role.
METHODS: SB-HCV was used to infect Molt-4 cells, and their cellular proliferation and CD44 expression was examined.
RESULTS: SB-HCV-infected Molt-4 cells expressed a significantly lower level of the CD44v6 isoform. The infected cells could be divided into 2 carboxyfluorescein succinimidyl ester (CFSE) groups, CFSE-high (indicating low proliferation activity; 34.2% of the cells) and CFSE-low (indicating high proliferation activity; 62.5% of the cells), whereas uninfected cells consisted of only a CFSE-low population. Of the CFSE-high cells, 82.4% were positive for the HCV protein NS5A, whereas only 1.2% of the CFSE-low cells were positive for this protein. Among the HCV proteins, NS5A alone caused the down-regulation of CD44v6 expression. After cells were stimulated with phorbol myristate acetate, the amount of phosphorylated mitogen-activated protein (MAP) kinase was significantly reduced in CFSE-high, SB-HCV-infected Molt-4 cells. After Fas ligand stimulation, SB-HCV-infected Molt-4 cells had increased cleavage of caspase 8 and 3 and enhanced apoptosis, compared with the rates of cleavage and apoptosis in control groups, indicating that SB-HCV infection increased Fas-mediated apoptosis.
CONCLUSION: HCV replication in T cells suppresses cellular proliferation and enhances susceptibility to Fas signaling by inhibiting CD44v6 signaling and expression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19199548      PMCID: PMC4174598          DOI: 10.1086/596739

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  47 in total

1.  Influence of HTLV-2 infection on hepatitis C virus replication in HIV-positive patients.

Authors:  Carlos Toro; Sylvina Bassani; Pilar Ríos; Victoria Jiménez; Nuria Camino; Vincent Soriano
Journal:  J Clin Virol       Date:  2005-04       Impact factor: 3.168

2.  Production of infectious hepatitis C virus in tissue culture from a cloned viral genome.

Authors:  Takaji Wakita; Thomas Pietschmann; Takanobu Kato; Tomoko Date; Michiko Miyamoto; Zijiang Zhao; Krishna Murthy; Anja Habermann; Hans-Georg Kräusslich; Masashi Mizokami; Ralf Bartenschlager; T Jake Liang
Journal:  Nat Med       Date:  2005-06-12       Impact factor: 53.440

3.  Robust hepatitis C virus infection in vitro.

Authors:  Jin Zhong; Pablo Gastaminza; Guofeng Cheng; Sharookh Kapadia; Takanobu Kato; Dennis R Burton; Stefan F Wieland; Susan L Uprichard; Takaji Wakita; Francis V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-06       Impact factor: 11.205

Review 4.  IL-10, T cell exhaustion and viral persistence.

Authors:  Shawn D Blackburn; E John Wherry
Journal:  Trends Microbiol       Date:  2007-03-01       Impact factor: 17.079

5.  Expression of CD44 variants in colorectal carcinoma quantified by real-time reverse transcriptase-polymerase chain reaction.

Authors:  Hong-Min Ni; Adrian Francis Peng Kheong Leong; Denis Cheong; Shing Chuan Hooi
Journal:  J Lab Clin Med       Date:  2002-01

Review 6.  CD44: functional relevance to inflammation and malignancy.

Authors:  M Yasuda; K Nakano; K Yasumoto; Y Tanaka
Journal:  Histol Histopathol       Date:  2002       Impact factor: 2.303

7.  Hepatitis C virus core protein activates ERK and p38 MAPK in cooperation with ethanol in transgenic mice.

Authors:  Takeya Tsutsumi; Tetsuro Suzuki; Kyoji Moriya; Yoshizumi Shintani; Hajime Fujie; Hideyuki Miyoshi; Yoshiharu Matsuura; Kazuhiko Koike; Tatsuo Miyamura
Journal:  Hepatology       Date:  2003-10       Impact factor: 17.425

8.  Hepatitis C virus (HCV)-induced immunoglobulin hypermutation reduces the affinity and neutralizing activities of antibodies against HCV envelope protein.

Authors:  Keigo Machida; Yasuteru Kondo; Jeffrey Y Huang; Yung-Chia Chen; Kevin T-H Cheng; Zhenyong Keck; Steven Foung; Jean Dubuisson; Vicky M-H Sung; Michael M C Lai
Journal:  J Virol       Date:  2008-04-16       Impact factor: 5.103

9.  Hepatitis C virus nonstructural protein 5A inhibits tumor necrosis factor-alpha-mediated apoptosis in Huh7 cells.

Authors:  Yuka Miyasaka; Nobuyuki Enomoto; Masayuki Kurosaki; Naoya Sakamoto; Nobuhiko Kanazawa; Takahiro Kohashi; Eri Ueda; Shinya Maekawa; Hideki Watanabe; Namiki Izumi; Chifumi Sato; Mamoru Watanabe
Journal:  J Infect Dis       Date:  2003-11-11       Impact factor: 5.226

Review 10.  Hepatitis C virus NS5A: tales of a promiscuous protein.

Authors:  Andrew Macdonald; Mark Harris
Journal:  J Gen Virol       Date:  2004-09       Impact factor: 3.891

View more
  23 in total

1.  Modulation of IL-2 expression after uptake of hepatitis C virus non-enveloped capsid-like particles: the role of p38 kinase.

Authors:  Elisavet Serti; Polyxeni P Doumba; George Thyphronitis; Panagiota Tsitoura; Konstantina Katsarou; Pelagia Foka; Manousos M Konstandoulakis; John Koskinas; Penelope Mavromara; Urania Georgopoulou
Journal:  Cell Mol Life Sci       Date:  2010-07-31       Impact factor: 9.261

2.  Lymphotropic HCV strain can infect human primary naïve CD4+ cells and affect their proliferation and IFN-γ secretion activity.

Authors:  Yasuteru Kondo; Yoshiyuki Ueno; Eiji Kakazu; Koju Kobayashi; Masaaki Shiina; Keiichi Tamai; Keigo Machida; Jun Inoue; Yuta Wakui; Koji Fukushima; Noriyuki Obara; Osamu Kimura; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2010-08-17       Impact factor: 7.527

Review 3.  Virologic and immunologic aspects of HIV-hepatitis C virus coinfection.

Authors:  Kara W Chew; Debika Bhattacharya
Journal:  AIDS       Date:  2016-10-23       Impact factor: 4.177

4.  Sequential immunological analysis of HBV/HCV co-infected patients during Peg-IFN/RBV therapy.

Authors:  Yasuteru Kondo; Yoshiyuki Ueno; Masashi Ninomiya; Keiichi Tamai; Yasuhito Tanaka; Jun Inoue; Eiji Kakazu; Koju Kobayashi; Osamu Kimura; Masahito Miura; Takeshi Yamamoto; Tomoo Kobayashi; Takehiko Igarashi; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2012-05-16       Impact factor: 7.527

Review 5.  Direct effects of hepatitis C virus on the lymphoid cells.

Authors:  Yasuteru Kondo; Tooru Shimosegawa
Journal:  World J Gastroenterol       Date:  2013-11-28       Impact factor: 5.742

6.  Hepatitis C virus protects human B lymphocytes from Fas-mediated apoptosis via E2-CD81 engagement.

Authors:  Zhihui Chen; Yongzhe Zhu; Yanli Ren; Yimin Tong; Xian Hua; Fenghui Zhu; Libin Huang; Yuan Liu; Yuan Luo; Wei Lu; Ping Zhao; Zhongtian Qi
Journal:  PLoS One       Date:  2011-04-19       Impact factor: 3.240

7.  Authentic Patient-Derived Hepatitis C Virus Infects and Productively Replicates in Primary CD4+ and CD8+ T Lymphocytes In Vitro.

Authors:  Georgia Skardasi; Annie Y Chen; Tomasz I Michalak
Journal:  J Virol       Date:  2018-01-17       Impact factor: 5.103

8.  Hepatitis B and C infections in HIV-1 patients on combination antiretroviral therapy (cART) in Ghana: implications for immunologic recovery, clinical response to treatment, and hepatotoxicity.

Authors:  Theophilus Benjamin Kwofie; Daniel Adigbli; James Osei-Yeboah; Emmanuel Ativi; Sylvester Yao Lokpo
Journal:  Heliyon       Date:  2021-05-28

9.  Complementary role of HCV and HIV in T-cell activation and exhaustion in HIV/HCV coinfection.

Authors:  Thijs Feuth; Joop E Arends; Justin H Fransen; Nening M Nanlohy; Karel J van Erpecum; Peter D Siersema; Andy I M Hoepelman; Debbie van Baarle
Journal:  PLoS One       Date:  2013-03-15       Impact factor: 3.240

10.  1(OH) vitamin D3 supplementation improves the sensitivity of the immune-response during Peg-IFN/RBV therapy in chronic hepatitis C patients-case controlled trial.

Authors:  Yasuteru Kondo; Takanobu Kato; Osamu Kimura; Tomoaki Iwata; Masashi Ninomiya; Eiji Kakazu; Masahito Miura; Takehiro Akahane; Yutaka Miyazaki; Tomoo Kobayashi; Motoyasu Ishii; Norihiro Kisara; Kumiko Sasaki; Haruo Nakayama; Takehiko Igarashi; Noriyuki Obara; Yoshiyuki Ueno; Tatsuki Morosawa; Tooru Shimosegawa
Journal:  PLoS One       Date:  2013-05-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.